[
  {
    "ts": null,
    "headline": "Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market",
    "summary": "Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level.",
    "url": "https://finnhub.io/api/news?id=60a4ee5be4a972feec27d0f9e7e804858baf41684a39b8645b6917204959c2d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744402157,
      "headline": "Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market",
      "id": 133881447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level.",
      "url": "https://finnhub.io/api/news?id=60a4ee5be4a972feec27d0f9e7e804858baf41684a39b8645b6917204959c2d0"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?",
    "summary": "We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and big […]",
    "url": "https://finnhub.io/api/news?id=4f0c44f630635a5cd554be92b5f70c9c966345391ae603f2efaa821ec707ffef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744401504,
      "headline": "Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?",
      "id": 133880879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and big […]",
      "url": "https://finnhub.io/api/news?id=4f0c44f630635a5cd554be92b5f70c9c966345391ae603f2efaa821ec707ffef"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma",
    "summary": "PRINCETON, N.J., April 11, 2025--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma",
    "url": "https://finnhub.io/api/news?id=2d75a032bf570a1727cf4602f8ca7a70198688117ab2c0b9f781dc9fa0316b18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744400940,
      "headline": "U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma",
      "id": 133880880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., April 11, 2025--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma",
      "url": "https://finnhub.io/api/news?id=2d75a032bf570a1727cf4602f8ca7a70198688117ab2c0b9f781dc9fa0316b18"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says",
    "summary": "Bristol-Myers Squibb (BMY) investors will be focused on the trajectory of Cobenfy, its schizophrenia",
    "url": "https://finnhub.io/api/news?id=4a7f2acc9a3a008f1cfdb399c452909507b5be6fce8556af7b65ebaf09e527ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744398775,
      "headline": "Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says",
      "id": 133880881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) investors will be focused on the trajectory of Cobenfy, its schizophrenia",
      "url": "https://finnhub.io/api/news?id=4a7f2acc9a3a008f1cfdb399c452909507b5be6fce8556af7b65ebaf09e527ee"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas",
    "summary": "By Stephen Nakrosis Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma. Opdivo, or nivolumab, plus...",
    "url": "https://finnhub.io/api/news?id=08b976a39f02ae70cf25304d5069198682ccb9c5ce44add637d549bc539dcb4d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744390153,
      "headline": "FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas",
      "id": 133881713,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Stephen Nakrosis Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma. Opdivo, or nivolumab, plus...",
      "url": "https://finnhub.io/api/news?id=08b976a39f02ae70cf25304d5069198682ccb9c5ce44add637d549bc539dcb4d"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "url": "https://finnhub.io/api/news?id=d7ed624044a165ef9e4f90ed98a5ca13b641b58b3a3ee802a806a6969c4982fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744377180,
      "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "id": 134146899,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "url": "https://finnhub.io/api/news?id=d7ed624044a165ef9e4f90ed98a5ca13b641b58b3a3ee802a806a6969c4982fc"
    }
  },
  {
    "ts": null,
    "headline": "3 Value Stocks in the Doghouse",
    "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
    "url": "https://finnhub.io/api/news?id=ad4ce6a20ed8433f5b113d08ce78fd8e6bedb80cdb2672938dbc440b5db7554a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744376516,
      "headline": "3 Value Stocks in the Doghouse",
      "id": 133880882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
      "url": "https://finnhub.io/api/news?id=ad4ce6a20ed8433f5b113d08ce78fd8e6bedb80cdb2672938dbc440b5db7554a"
    }
  },
  {
    "ts": null,
    "headline": "Warning For SCHD Investors: Tariffs Are A Major Risk",
    "summary": "The Schwab U.S. Dividend Equity ETF typically offers stability, yet global trade tensions could expose its vulnerabilities. Find out why SCHD is rated hold.",
    "url": "https://finnhub.io/api/news?id=ce64faef5d8491da1826cf994e1f689a332e53ea257d21af991eb4bc2a897c0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744359300,
      "headline": "Warning For SCHD Investors: Tariffs Are A Major Risk",
      "id": 133878500,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/174676710/image_174676710.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Schwab U.S. Dividend Equity ETF typically offers stability, yet global trade tensions could expose its vulnerabilities. Find out why SCHD is rated hold.",
      "url": "https://finnhub.io/api/news?id=ce64faef5d8491da1826cf994e1f689a332e53ea257d21af991eb4bc2a897c0c"
    }
  }
]